Many researchers have until now united their efforts in the endeavor to discover new
anticoagulants, which would be simpler to use and safer to administer, so that patients …

“Hot Topics.” Seminars in Thrombosis & Hemostasis last published “Hot Topics” issues in
late 20071 and early 2008. 2 Those issues were very popular with our readers, as identified …

Evaluation of: Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the
treatment of acute venous thromboembolism. N. Engl. J. Med. 361, 2342–2352 (2009) …

Since the quest for a better replacement of warfarin started several decades ago and new
compounds were brought forward to clinical trials, the concept of an ideal anticoagulant …

For over half a century, warfarin or other vitamin K antagonists (VKA)(such as
acenocoumarol, available in Greece and other countries), have been the gold standard and …

Background Dabigatran is a direct thrombin inhibitor and an anticoagulant that is prescribed
to prevent ischemic stroke and systemic embolism in non-valvular atrial fibrillation …

For the last 60 years warfarin has been the cornerstone for chronic anticoagulation in
prevention of ischemic strokes and systemic embolization. Warfarin therapy has several …

Thromboembolic disease is a major cause of mortality and morbidity in the developed world
and is caused by an excessive stimulation of coagulation. Thrombin is a key serine protease …

Atrial fibrillation (AF) affects more than 3 million Americans and is expected to reach
epidemic proportions as the US population ages. The presence of AF increases lifetime …

Dabigatran etexilate is the first commercially available oral direct thrombin inhibitor. A single
trial has studied patients at risk for stroke associated with nonvalvular atrial fibrillation; in this …